OncoPep

About:

OncoPep is a developer of a multi-peptide therapeutic vaccine to prevent the progression of cancer.

Top Investors: Leukemia & Lymphoma Society, Crystal Bioscience, Kukje Pharma, Tera Science

Description:

OncoPep, Inc. was founded in 2010 to commercialize a novel approach to developing targeted immunotherapeutics against cancer. The company's proprietary core technology was developed in the laboratory of Dr. Kenneth Anderson, M.D., a world leader in cancer treatment, at the Dana Farber Cancer Institute. The technology, which OncoPep has exclusively licensed from Dana Farber, employs a unique combination of proprietary peptides to form a therapeutic cancer vaccine. Vaccines developed from this technology are designed to stimulate the patient’s immune system to attack his or her cancer through an optimized combination of disease-specific peptides and adjuvants (substances that stimulate the immune system).

Total Funding Amount:

$28.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

North Andover, Massachusetts, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)OncoPep.com

Founders:

Ken Anderson, Marc Cohen

Number of Employees:

1-10

Last Funding Date:

2021-12-10

IPO Status:

Private

Industries: